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Abstract
Dengue fever is a re-emergent and challenging public health problem in the world. Here, we assess
retrospectively the epidemiological and clinical characteristics of the 2002 dengue epidemic in the
state of Colima, Mexico. This study is carried out by analysing a database containing demographic,
epidemiological and clinical information. Of the 4040 clinical dengue cases diagnosed in the hospitals
of the Mexican Institute of Public Health in the state of Colima, 548 cases were confirmed by laboratory
tests, and 495 cases presented at least one haemorrhagic manifestation. Of the total clinically diagnosed
cases, the most common symptoms observed were: fever (99.6%), headache (92.4%), myalgia (89.4%)
and arthralgia (88.6%). The most common haemorrhagic manifestations were: petechiae (7.1%), gingivitis
(3.4%) and epistaxis (3.6%). The median time between the onset of illness and visit to the health care
clinic (diagnostic delay) was 1 day (interquartile range [IQR]: 0-3). For cases presenting haemorrhagic
manifestations, the diagnostic delay was higher (median: 2 days, IQR: 0-4) than for non-haemorrhagic
cases (median: 1 day, IQR: 0-3). The proportion of males presenting haemorrhagic manifestations was
higher than females (Fisher Exact test; p<0.01). Moreover, the age group 0-5 years presented a lower
proportion of cases with haemorrhagic manifestations compared with the age group of 6 years and
older (p=0.0281). No significant differences were found between the diagnostic delays in the case of
males and females.
Keywords: Dengue fever; Clinical diagnostic delay; Haemorrhagic; Colima; Mexico.
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Introduction
Annually there are approximately 100 million
cases of dengue worldwide.[1] It is endemic in
Africa, the Americas, the Eastern
Mediterranean, South-East Asia and the
Western Pacific regions. The challenges seem
daunting. For example, in Singapore, dengue
is a major public health problem despite the
fact that a set of extraordinary control efforts
have been put into place over the past few
years.[2] The etiological agent is a Flavivirus with
four different serotypes (DENV-1–4). The
primary vectors of dengue are mosquitoes of
the species Aedes aegypti and Aedes albopictus.
Humans are infected when bitten by feeding
infectious females. Those who recover may
become permanently immune to the serotype
involved and partially immune to the other
serotypes.[3] Susceptible vectors acquire the
infection when feeding on infectious humans.
Female mosquitoes are responsible for the
transmission of the virus since males are nonblood suckers and feed primarily on plants and
flowers.[4]
Cases of dengue are classified as
asymptomatic, clinically non-specific flu-like
symptoms, dengue fever (DF), dengue
haemorrhagic fever (DHF) and dengue shock
syndrome (DSS).[5] DHF and DSS are the severe
forms of the disease. Dengue attack rates vary
from 40% to 50% but may be as high as 80%
to 90%.[6]

cases of DHF.[9] We report the results of a
retrospective study on the epidemiological and
clinical characteristics of the 2002 (serotype
DENV-2) dengue epidemic in the state of
Colima, Mexico.[10]

Materials and methods
The epidemiological and clinical characteristics
of dengue fever cases recorded during the
2002 epidemic (January through December)
in the state of Colima have been studied. The
state of Colima is located on the Pacific coast,
has a tropical climate, and has a population of
488 028 (Figure 1).[11] The data used include
cases diagnosed at the hospitals of the Mexican
Institute of Public Health (IMSS). The IMSS are
a collection of state hospitals that provide
primary health services to 60% of the
population in the state. The remaining
population receives health care services from
the hospitals of the Mexican Health Ministry
and the private sector.
Figure 1: Map of the state of Colima,
Mexico, with divisions by municipalities
Armería (1), Colima (2), Comala (3),
Coquimatlán (4), Cuauhtémoc (5),
Ixtlahuacán (6), Manzanillo (7), Minatitlán
(8), Tecomán (9), Villa de Alvarez (10)

Mexico was declared dengue-free when
the principal vector, Ae. aegypti, was eliminated
in 1963. However, Ae. aegypti reappeared two
years later and the disease returned.[7] All the
four dengue serotypes are now circulating in
Mexico since 1980.[7] DHF has become a
public health problem in the country since
1994.[8] In 2002, over 30 Latin American
countries reported a total of over a million cases
of classical dengue as well as more than 17 000

Dengue Bulletin – Volume 31, 2007

27

Clinical diagnostic delays and dengue fever in Colima, Mexico (2002)

Patient record data are stratified by
municipality where the dengue cases were
diagnosed (Figure 1); the week of symptom
onset and diagnosis; the IgM antibody test
result; patient’s age and gender; and diagnostic
delay (as presented later in the paper).
Furthermore, non-haemorrhagic recorded
symptoms included: fever, headache, myalgia,
arthralgia, retro-orbital pain, exanthema,
diarrhoea, vomit, nausea, pruritus, chills,
photophobia, abdominal pain, conjunctivitis,
nasal decongestion, cough, hepatomegaly and
splenomegaly. Haemorrhagic recorded
symptoms included: petechiae, ecchymosis,
ascites, pleural effusion, gingivitis, epistaxis,
haematemesis and melena. We classified a
patient as “delayed” when clinical diagnosis was
made two days after the onset of symptoms.
The World Health Organization (WHO)
case definition of probable dengue cases[3]
requires the presence of fever or chills and at
least two symptoms from: myalgia, arthralgia,
retro-orbtial pain, headache, rash, or some
haemorrhagic manifestation (e.g. petechiae,
haematuria, haematemesis, melena). The
laboratory testing was only carried out in a small
subset of the clinically diagnosed dengue cases
through anti-dengue IgM antibody tests (ELISA).
We classified cases of DHF following as
closely as possible all the four requirements
for the WHO definition of DHF (fever,
haemorrhage, thrombocytopenia, and signs of
plasma leakage).[6] Difficulties arose because
basic measurements, such as platelet counts,
were conducted in only 1227 (30%) of the
cases and signs of plasma leakage were assessed
only clinically (pleural effusion and/or ascites).
The difficulties in characterizing DHF cases
using the WHO system have led some
investigators to use modified classification
schemes.[12,13] Here, we used the number of
haemorrhagic symptoms as a measure of
disease severity and classify dengue patients
as haemorrhagic whenever one haemorrhagic
symptom was reported. Dengue cases that did
28

not exhibit haemorrhagic manifestations were
classified as non-haemorrhagic.
We characterize variations using the mean
and standard deviation (SD). Proportions are
compared using Fisher’s exact test of
independence, which uses a hypergeometric
sampling distribution for cell frequencies.[14]
Population distributions are compared using the
non-parametric Wilcoxon test. Results are
deemed significant when the p value is less
than 0.05. Some records are not complete.
For example, the date of symptom onset was
only recorded in 2242 patient records. Hence,
the number of records (denoted by N) used is
included in the analyses.

Results
The 2002 dengue epidemic in Colima, Mexico,
began in January, peaked in September and
died out in December (Figure 2). Four
thousand and forty cases were clinically
diagnosed, including 495 cases with
haemorrhagic manifestations. A total of 555
clinical dengue cases (14%) were subjected
to ELISA test and 548 cases were positive for
anti-dengue IgM antibodies. Thrombocytopenia
was detected in 528 cases but platelet counts
were only recorded for 1227 cases (30%). Both
thrombocytopenia and haemorrhagic
symptoms were present in 203 cases (17%,
N=1227), but only 8 cases could be classified
as DHF under the WHO classification. The
distribution of dengue cases by municipality is
given in Table 1. The mean age of a dengue
case was 24.61 ± 16.30 (SD) years (Figure
3A). The attack rate was about 9.5 dengue
cases per 1000 persons. This rate was reported
among two age groups of 5-14 and 25-34 years.
The male/female ratio was about 1:1 with 2045
(50.6%) males and 1993 (49.4%) females. We
found no significant difference between the
age distribution of non-haemorrhagic and
haemorrhagic cases (Wilcoxon test, p=0.5018,
N=4007).
Dengue Bulletin – Volume 31, 2007
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Figure 2: The weekly number of clinical haemorrhagic and non-haemorrhagic dengue cases
during the course of the 2002 dengue epidemic in Colima, Mexico
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Table 1: Number of dengue cases reported by municipality and classified as haemorrhagic and
non-haemorrhagic
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Figure 3: Age (A) and effective diagnostic delay (B) distributions of dengue cases presenting
haemorrhagic and non-haemorrhagic manifestations during the 2002 dengue epidemic in
Colima, Mexico

The most common symptoms in nonhaemorrhagic dengue patients were fever
(99.6%), headache (92.4%), myalgia (89.4%)
and arthralgia (88.6%), while the least common
symptoms were hepatomegaly (3.3%) and
splenomegaly (2.3%). For haemorrhagic
dengue cases, the median number of
haemorrhagic manifestations was 1
(interquartile range [IQR]: 1-2) with a range
from 1 to 7. The most common haemorrhagic
manifestations were petechiae (7.1%), gingivitis
(3.4%) and epistaxis (3.6%), while the least
were ascites (0.3%) and pleural effusion (0.1%).
The relative frequency of symptom appearance
is displayed in Table 2.

30

The median diagnostic delay was 1 day
(IQR: 0-3) with a range of 0 to 22 days
(N=2242). Significant differences between the
diagnostic delay distributions of nonhaemorrhagic and haemorrhagic cases were
obtained (Figure 3B, Wilcoxon test, p=0.0004,
N=2242). In fact, the proportion of cases that
experienced haemorrhagic manifestations and
a diagnostic delay greater than two days was
significantly higher than those with a diagnostic
delay less than or equal to two days (17.4 vs
9.9%, p<0.0001, N= 2283; Fisher’s exact
test). The median diagnostic delay for
haemorrhagic cases was 2 days (IQR: 0-4;
range: 0-14) that is higher than for nonhaemorrhagic cases, for which the median
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Table 2: Frequency of clinical symptoms
presented in dengue cases during the 2002
outbreak in Colima, Mexico
(Because some data were not completely
recorded, we provide both the numerator (n)
and denominator (N) used to compute the
frequencies)
Characteristic

Positive, % (n/N)

Non-haemorrhagic
manifestations
Fever

99.6 (4009/4025)

Headache

92.4 (3707/4013)

Myalgia (muscle pain)

89.4 (3586/4010)

Arthralgia (joint pain)

88.6 (3550/4006)

Retro orbital pain

73.3 (2936/4004)

Chills

58.1 (2334/4018)

Nausea

52.5 (2107/4015)

Vomit

36.7 (1476/4023)

Photophobia

33.2 (1331/4006)

Abdominal Pain

32.4 (1299/4014)

Exanthema (skin rash)

30.3 (1217/4019)

Conjunctivitis (pink eye)

26.1 (1046/4010)

Pruritus (itching)

25.6 (1027/4015)

Diarrhea

18.3 (736/4019)

Cough

17.5 (702/4013

Nasal decongestion

17.3 (694/4003)

Hepatomegaly
(liver enlargement)

3.3 (128/3938)

Splenomegaly
(spleen enlargement)

2.3 (90/3940)

Haemorrhagic manifestations
Petechiae
(small purplish spots)

7.1 (268/3761)

Epistaxis (nosebleed)

3.6 (136/3748)

Gingivitis (bleeding gums)

3.4 (126/3747)

Haematemesis
(vomiting blood)

1.5 (58/3747)

Ecchymosis (bruising)

1.4 (52/3745)

Melena (blood in stool)

1.1 (41/3743)

Haematoma

0.6 (22/3746)

Ascites

0.3 (10/3741)

Pleural effusion

0.1 (5/3733)
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diagnostic delay was 1 day (IQR: 0-3; range:
0-22). The proportion of cases with a diagnostic
delay less than or equal to 2 days was
significantly higher for children (<=15 years)
than for adults (>15 years) (73% vs 67%,
p=0.001, N=2283, Fisher’s exact test). No
significant association between short diagnostic
delay (less than or equal to 2 days) and gender
(p=0.36, Fisher’s exact test, N=2281) was
found. The median diagnostic delay turned out
to be 3 days (IQR: 0-4) (N=114) for cases
with both haemorrhagic manifestations and
thrombocytopenia.
A significant association between the
presence of haemorrhagic manifestations and
age was found. In fact, the 0-5 years age group
supported a lower proportion of cases with
haemorrhagic manifestations than the age
group of 6 years and older (8.7 vs 12.7%,
p=0.0281, Fisher’s exact test, N=4007). A
significant association between the presence
of haemorrhagic manifestations and gender was
also identified. In fact, the proportion of males
(13.6%) with haemorrhagic dengue was higher
than for females (10.8%) (p=0.0072; N=4038;
Fisher’s exact test).

Discussion
A retrospective study on the clinical and
epidemiological characteristics of dengue was
carried out during the 2002 epidemic in
Colima. The levels of association significance
were assessed between disease severity and
epidemiological, clinical and demographic
variables. We did not find a correlation between
dengue disease and gender. The 1:1 female/
male ratio is in agreement with other dengue
studies conducted in Nicaragua,[15] Thailand[16]
and Taiwan. [17] Males in our study were
statistically more likely to experience
haemorrhagic manifestations, a finding that
agrees with a study conducted in Nicaragua.[15]
We found a significantly higher median
31
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diagnostic delay for cases presenting
haemorrhagic manifestations than for nonhaemorrhagic cases.
Not surprisingly, this finding indicates an
important correlation between the disease’s
clinical evolution and diagnostic delay.
Diagnostic delays may complicate the clinical
state of the patient while facilitating the
transmission of dengue in the population. In
other words, although interventions have
shown to be incapable of reverting a dengue
epidemic,[18] reductions in the diagnostic delays
can reduce the final epidemic size.
Mathematical models of dengue transmission
have shown that educational campaigns aiming
at shortening the diagnostic delays can lead to
significant reductions in the final epidemic
size.[19] Control strategies that benefit from a
prompt identification of dengue cases include
the use of nets and screens, the application of
insecticides to clothing and the application of
mosquito repellents. Moreover, strategies
aiming at the elimination or reduction in the
number of breeding sites through the use of
larvicidal control including ovitraps[20] and
malathion spraying for adult control can also
reduce the dengue burden.
A fever alone is usually not enough to
motivate patients to seek medical care. It is only
the presence of severe symptoms (e.g.
haemorrhagic manifestations) that motivate to
seek medical care. This observation may explain
the significant association that we found
between diagnostic delays and the presence of
haemorrhagic manifestations. Specifically, we
found that the proportion of cases with a
diagnostic delay of less than or equal to 2 days
was significantly higher for children (<=15 years)
than for adults (>15 years). This is in agreement
with the findings by Ahorlu et al.[21] who studied
the socio-cultural determinants of treatment
delay for childhood malaria in southern Ghana.
Ahorlu et al.[21] found that families with similar
economic situations who have sick children will
32

be more likely to seek treatment. Gender
exhibited no correlation with the length of the
diagnostic delays. The most common
explanations for diagnostic delays in malaria
studies in sub-Saharan Africa include poverty and
the inability to pay for treatment. [22] This
perspective could not be assessed here as most
of the patients comprised only the insured
individuals by IMSS. In summary, a combination
of cultural factors, the inability to distinguish
dengue illnesses from traditional fevers at the
early stages of the disease, and the differentiated
treatment are the main factors behind
differences in diagnostic delays.
The impact of dengue diagnostic delay
distributions and their association with clinical,
demographic and epidemiological factors have
not received much attention. This contrasts, for
example, with epidemiological studies dealing
with other infectious diseases such as pulmonary
tuberculosis. [23] However, there are some
relevant studies. For example, an estimate of
the median diagnostic delay of 5 days has been
reported for the 1996 dengue epidemic in
north-eastern Brazil,[24] that is, a significantly
longer median diagnostic delay than our
estimate of 1 day. Guzman et al.[25] found that
the average time from fever onset to
hospitalization associated with the 1997 dengue
outbreak in Cuba was about 2.9 days. On the
other hand, a median diagnostic delay of 2 days
was reported for malaria-stricken travellers
returning to Sweden during 1994 to 2001.[26]
We found a lower proportion of
haemorrhagic cases in the age group 0-5 years
than those in the age group of 6 years and older.
Secondary dengue infections have been
associated with the presence of haemorrhagic
manifestations, a phenomenon explained by the
theory of antibody-dependent enhancement.[5]
Seasonal effects are also critical. The peak
of the epidemic in Colima occurred in midSeptember, which correlates well with the
Dengue Bulletin – Volume 31, 2007
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peak in the rainfall.[27] A similar pattern has
been reported for other dengue outbreaks
{Nicaragua (1998),[15] El Salvador (2000)[28] and
Bangladesh (2000)[29]}.
In contrast to dengue hyperendemic areas
where dengue haemorrhagic fever is primarily
a disease of children under 15 years, we found
a lower proportion of haemorrhagic cases in
the age group 0-5 years compared to the age
group of 6 years and older.
The number of dengue infections per
municipality was determined by the location of
the patient’s address albeit the actual dengue
infection may have occurred at work because
dengue mosquitoes are daytime feeders.[30]
This study was limited by the lack of
complete medical records. Difficulties were
encountered in rigorously following the WHO
classification scheme for DHF, because the
signs of plasma leakage were assessed only
clinically (pleural effusion and/or ascites). The
number of DHF cases may in fact be as high
as 203, that is, the number of cases for which
the other three requirements of the WHO
classification scheme for DHF (fever,
haemorrhage and thrombocytopenia) were
satisfied. On the other hand, dengue cases with
severe haemorrhage, not accompanied by
increased vascular permeability, have been
reported from several regions of the world

including Indonesia, China, India, Philippines,
Thailand, South Pacific and Latin America.[13]
To improve the tracking of dengue, workers at
IMSS hospitals would need to collect as
complete patient information as possible. Efforts
to follow the WHO classification guidelines as
closely as possible would be quite helpful.
Dengue symptoms can be confused in the
epidemic and non-epidemic situations with
other exanthematous and non-exanthematous
viral diseases such as measles, rubella,
enteroviruses and influenza.[31] We recognize
that there are limited resources for laboratory
testing. In the 2002 dengue epidemic in
Colima, only 14% of the clinical dengue cases
were tested in the laboratory for anti-dengue
IgM. The low proportion of clinical dengue
cases tested serologically make it difficult to
validate some of our findings.
Our findings indicate that an educational
campaign in the community with the objective
of informing the population about early
symptoms of dengue infection could lead to
not only reductions in diagnostic delays but also
to reduce the final size of a dengue epidemic.
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